… This randomised, double-blind, parallel-group trial was undertaken in 802 centres in 46 … a
TIA in the previous 8 days were randomly allocated with a central interactive response system …

… The study utilised a randomised, double-blind, placebo-controlled, parallel group design.
This design has not been commonly used in studies of canine osteoarthritis (Vasseur and …

… We did a double-blind, parallel-group, randomised controlled trial. Patients with secondary
progressive multiple sclerosis aged 18–55 years were eligible if they had an expanded …

… Methods Phase III randomised, double-blind, multicentre, multinational, parallel-group study.
Patients with active disease despite MTX (12.5–25 mg/week) were randomised to receive 3 …

… This study examines the safety and efficacy of daily, oral risedronate therapy for the … This
multicenter, randomized, double- blind, placebo-controlled, parallel-group study was conducted …

… This study is one of the few randomised, controlled, clinical trials to examine longer term
management of moderate to severe atopic dermatitis. Rather than focusing on initial healing …

… Study design This phase III, randomised, double-blind, parallel-group study was conducted
… Patients were randomised in a 1:1 ratio to receive 50 mg of either SB4 or ETN (see online …

… randomised, double-blind, parallel-group trial, undertaken at 13 clinics in South Africa, Tanzania,
Uganda, and Zambia. We randomly … groups for 52 weeks (up to 104 weeks in Uganda). …

… The safety profiles between groups were similar in this study and consistent with previous
studies … In this study, the proportion of patients in both groups who developed anti-tocilizumab …

… Methods: Randomized, double-blind, active-controlled, double-dummy, parallel-group study
in which 185 patients were randomized to receive up to 120 mg/day of OXN PR or OxyPR …